Cite
Planchard D, Besse B, Groen HJM, et al. Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. J Thorac Oncol. 2021;17(1):103-115doi: 10.1016/j.jtho.2021.08.011.
Planchard, D., Besse, B., Groen, H. J. M., Hashemi, S. M. S., Mazieres, J., Kim, T. M., Quoix, E., Souquet, P. J., Barlesi, F., Baik, C., Villaruz, L. C., Kelly, R. J., Zhang, S., Tan, M., Gasal, E., Santarpia, L., & Johnson, B. E. (2022). Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 17(1), 103-115. https://doi.org/10.1016/j.jtho.2021.08.011
Planchard, David, et al. "Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer vol. 17,1 (2022): 103-115. doi: https://doi.org/10.1016/j.jtho.2021.08.011
Planchard D, Besse B, Groen HJM, Hashemi SMS, Mazieres J, Kim TM, Quoix E, Souquet PJ, Barlesi F, Baik C, Villaruz LC, Kelly RJ, Zhang S, Tan M, Gasal E, Santarpia L, Johnson BE. Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. J Thorac Oncol. 2022 Jan;17(1):103-115. doi: 10.1016/j.jtho.2021.08.011. Epub 2021 Aug 26. PMID: 34455067.
Copy
Download .nbib